Literature DB >> 28775554

LIVER RESECTION FOR METASTASES FROM COLORECTAL CANCER.

H G Mukhopadhyay1, L S Vohra2, A K Sharma3, R Solanki4, P S Reddy5, G S Chopra6, P Subhas7.   

Abstract

Five percent of patients with liver secondaries from colorectal carcinoma are potentially resectable and several studies have demonstrated significantly improved survival following resection. Two hundred and ten patients operated for colorectal carcinoma were followed up. Computed tomography confirmed potentially resectable metastasis to the liver in 38. On exploration 18 patients who had 4 or less hepatic metastases and no extrahepatic disease, underwent resection of their secondaries. Fourteen were males and 4 females with a mean age of 43.5 (SD 13.6, range 18-72) years. Ten patients presented with synchronous liver metastasis and 8 had metachronous disease. There was no post-operative mortality. All 18 have been followed up. for a median period of 23.5 (range 12-38) months. Seven patients are alive and well with no evidence of recurrence at a median period of 28 months (survival 39%). Four are alive with local recurrence in the liver. Median time to recurrence was 22 months. Seven patients have died of disseminated disease. The disease free survival at 28 months is 39% and the overall survival 61%. A close follow-up protocol for all patient undergoing curative surgery for colorectal cancer is essential, if such patients are to be selected early.

Entities:  

Keywords:  Colorectal cancer; Liver resection; Metastases

Year:  2017        PMID: 28775554      PMCID: PMC5531738          DOI: 10.1016/S0377-1237(17)30302-7

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  18 in total

1.  Late results justify resection for multiple hepatic metastases from colorectal cancer.

Authors:  M Rees; G Plant; S Bygrave
Journal:  Br J Surg       Date:  1997-08       Impact factor: 6.939

2.  Improved staging of liver tumors using laparoscopic intraoperative ultrasound.

Authors:  D J Barbot; J H Marks; R I Feld; J B Liu; F E Rosato
Journal:  J Surg Oncol       Date:  1997-01       Impact factor: 3.454

3.  Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging.

Authors:  J P Heiken; P J Weyman; J K Lee; D M Balfe; D Picus; E M Brunt; M W Flye
Journal:  Radiology       Date:  1989-04       Impact factor: 11.105

4.  Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie.

Authors:  D Jaeck; P Bachellier; M Guiguet; K Boudjema; J C Vaillant; P Balladur; B Nordlinger
Journal:  Br J Surg       Date:  1997-07       Impact factor: 6.939

5.  Laparoscopic screening of surgical candidates with pancreatic cancer or liver tumors.

Authors:  W P Reed; I A Mustafa
Journal:  Surg Endosc       Date:  1997-01       Impact factor: 4.584

6.  Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer.

Authors:  D A August; P H Sugarbaker; P D Schneider
Journal:  Cancer       Date:  1985-04-01       Impact factor: 6.860

Review 7.  Resection of hepatic metastases from colorectal cancer. Biologic perspective.

Authors:  G Steele; T S Ravikumar
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

8.  Detection of hepatic metastases in colorectal cancer: a prospective study of laboratory and imaging methods.

Authors:  B Ohlsson; K G Tranberg; C Lundstedt; H Ekberg; E Hederström
Journal:  Eur J Surg       Date:  1993-05

9.  A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions.

Authors:  M M Kemeny; P H Sugarbaker; T J Smith; B K Edwards; T Shawker; M Vermess; A E Jones
Journal:  Ann Surg       Date:  1982-02       Impact factor: 12.969

10.  Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients.

Authors:  B Nordlinger; M A Quilichini; R Parc; L Hannoun; E Delva; C Huguet
Journal:  Ann Surg       Date:  1987-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.